The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SCRUM-Japan MONSTAR-SCREEN-3: Comprehensive tumor microenvironment analysis via multi-omics in a large-scale prospective study.
 
Mitsuho Imai
Patents, Royalties, Other Intellectual Property - 1. ?NCC's Reference: #2023-03 Filing number (Filing date): US 63/468,666 (2023.05.24) Title: METHOD OF USING AN ARTIFICIAL INTELLIGENCE-POWERED WHOLE SLIDE IMAGE (WSI) ANALYSIS TO PREDICT TUMOR RESPONSE TO SUBSEQUENT IMMUNE CHECKPOINT INHIBITOR TREATMEN
 
Shingo Sakashita
No Relationships to Disclose
 
Junichiro Yuda
Research Funding - Abbvie; Amgen; AstraZeneca; Brighpath Bio; Bristol-Myers Squibb/Celgene; Celeid Therapeutics; Chugai Pharma; Daiichi Sankyo; Genmab; Incyte; Janssen; Mitsubishi Tanabe; MSD; Novartis; Sanofi; Sumitomo Pharma; Takeda
 
Shin Kobayashi
No Relationships to Disclose
 
Riu Yamashita
Consulting or Advisory Role - Takeda
 
Tadayoshi Hashimoto
Honoraria - Cytogen; Takata Pharmaceutical
 
Takao Fujisawa
Honoraria - Amelief; AstraZeneca; Merck Serono
 
Taro Shibuki
No Relationships to Disclose
 
Shun-ichiro Kageyama
Research Funding - Boehringer Ingelheim
 
Yoshikatsu Koga
No Relationships to Disclose
 
Michiko Nagamine
Honoraria - GxD, Inc; Matsunami Glass Ind.,Ltd.; SRL Diagnostics
 
Takeshi Kuwata
Honoraria - Astellas Pharma; Bayer; Daiichi Sankyo; FALCO biosystems; MSD; Roche
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo; Roche
Research Funding - Takeda (Inst)
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yoshiaki Nakamura
Consulting or Advisory Role - DAIICHI SANKYO Co., Ltd.; Exact Sciences; Gilead Sciences; Guardant Health Pte Ltd; Natera,Inc.; Premo Partners, Inc.; Roche Ltd./; Seagen,Inc.; Takeda
Speakers' Bureau - Becton Dickinson; CareNet,Inc.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health Japan Corp.; Guardant Health Pte Ltd; Hisamitsu Pharmaceutical; Merck; Miyarisan pharmaceutical; MSD K.K; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health AMEA, Inc. (Inst); Roche (Inst); Seagen,Inc. (Inst); Tempus (Inst)
 
Woong-Yang Park
Employment - GxD Inc.
Leadership - GxD Inc.
Stock and Other Ownership Interests - GENINUS
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)